[Studies on chemotherapy in adenocarcinoma of the uterine cervix using xenografts transplanted in nude mice].
Adenocarcinoma of the human uterine cervix was successively transplanted into nude mice and the effects of chemotherapy on adenocarcinoma of uterine cervix were investigated in this transplanted tumor. First, it was confirmed that both the original tumor and the transplanted tumor were apparently histologically the same as adenocarcinoma of the uterine cervix (endocervical type). And the transplanted tumor was shown to have the features of adenocarcinoma by observation it under an electron microscope. The doubling time of the transplanted tumor was 9.2 +/- 1.4 days (means +/- SD). For the chemotherapy study, first the therapeutic effects of 11 kinds of agents were screened by single-agent chemotherapy applied to the transplanted tumor. From the results of this series, 6 regimens for multi-agent chemotherapy were tried on the transplanted tumor. The effects of the chemotherapy were evaluated following Battelle Columbus Laboratories Protocol and histopathologically. The relative regression rates for the tumors treated with mitomycin C(MMC) + cyclophosphamide (CPM) and MMC + CPM + methotrexate (MTX) were 72.9% and 80.9% (Tn/T0 = 0.84), respectively. Histological effects were found in only these. The results suggest that the combinations of MMC + CPM or MMC + CPM + MTX are regimens that are possibly effective on the adenocarcinoma of human uterine cervix and are worth be trying clinically.
Yamagishi
M
M
Department of Obstetrics and Gynecology, Faculty of Medicine, Toyama Medical and Pharmaceutical University.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D051379:Mice; D008819:Mice, Nude; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009368:Neoplasm Transplantation; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
D008937:Mitomycins; D016685:Mitomycin; D003520:Cyclophosphamide; D008727:Methotrexate